182 related articles for article (PubMed ID: 37536937)
1. Multiple TMA-aided CRISPR/Cas13a platform for highly sensitive detection of IL-15 to predict immunotherapeutic response in nasopharyngeal carcinoma.
Wu YX; Xing S; Wang Y; Tian BY; Wu M; Wang XP; Huang Q; He X; Chen SL; Li XH; Zeng MS; Liu WL
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37536937
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study.
Tang XR; Li YQ; Liang SB; Jiang W; Liu F; Ge WX; Tang LL; Mao YP; He QM; Yang XJ; Zhang Y; Wen X; Zhang J; Wang YQ; Zhang PP; Sun Y; Yun JP; Zeng J; Li L; Liu LZ; Liu N; Ma J
Lancet Oncol; 2018 Mar; 19(3):382-393. PubMed ID: 29428165
[TBL] [Abstract][Full Text] [Related]
3. Effect of platelet activating factor and butyrate on the expression of interleukin-2 receptor alpha in nasopharyngeal carcinoma cells.
Tsai MH; Chiou SH; Chow KC
Int J Oncol; 2001 Nov; 19(5):1049-55. PubMed ID: 11605008
[TBL] [Abstract][Full Text] [Related]
4. Rta-IgG as a biomarker for diagnosis and post treatment prognostic of nasopharyngeal carcinoma.
Xu XF; Lu RQ; Xiao R; Zhou L; Zhao XM; Hu XC; Gao X; Guo L
Cancer Biomark; 2016; 16(3):467-76. PubMed ID: 27062704
[TBL] [Abstract][Full Text] [Related]
5. Serum miRNAs, a potential prognosis marker of loco-regionally advanced nasopharyngeal carcinoma patients treated with CCRT.
Zhang Z; Huang J; Wang G; Jin F; Zheng J; Xiao H; Lei L; Luo J; Chen C
BMC Cancer; 2020 Mar; 20(1):183. PubMed ID: 32131777
[TBL] [Abstract][Full Text] [Related]
6. CD3+T-lymphocyte infiltration is an independent prognostic factor for advanced nasopharyngeal carcinoma.
Al-Rajhi N; Soudy H; Ahmed SA; Elhassan T; Mohammed SF; Khoja HA; Ghebeh H
BMC Cancer; 2020 Mar; 20(1):240. PubMed ID: 32199452
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic values of serum cathepsin B and D in patients with nasopharyngeal carcinoma.
Tan G; Liu Q; Tang X; Kang T; Li Y; Lu J; Zhao X; Tang F
BMC Cancer; 2016 Mar; 16():241. PubMed ID: 26995190
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus serology as a potential screening marker for nasopharyngeal carcinoma among high-risk individuals from multiplex families in Taiwan.
Coghill AE; Hsu WL; Pfeiffer RM; Juwana H; Yu KJ; Lou PJ; Wang CP; Chen JY; Chen CJ; Middeldorp JM; Hildesheim A
Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1213-9. PubMed ID: 24769890
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas13a Signal Amplification Linked Immunosorbent Assay for Femtomolar Protein Detection.
Chen Q; Tian T; Xiong E; Wang P; Zhou X
Anal Chem; 2020 Jan; 92(1):573-577. PubMed ID: 31849223
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas9-mediated double knockout of SRPK1 and SRPK2 in a nasopharyngeal carcinoma cell line.
Prattapong P; Ngernsombat C; Aimjongjun S; Janvilisri T
Cancer Rep (Hoboken); 2020 Apr; 3(2):e1224. PubMed ID: 32671994
[TBL] [Abstract][Full Text] [Related]
11. A novel rapid visual detection assay for Toxoplasma gondii combining recombinase-aided amplification and lateral flow dipstick coupled with CRISPR-Cas13a fluorescence (RAA-Cas13a-LFD).
Zhao J; Li Y; Xue Q; Zhu Z; Zou M; Fang F
Parasite; 2022; 29():21. PubMed ID: 35420541
[TBL] [Abstract][Full Text] [Related]
12. Specific High-Sensitivity Enzymatic Molecular Detection System Termed RPA-Based CRISPR-Cas13a for Duck Tembusu Virus Diagnostics.
He D; Liu G; Yang J; Jiang X; Wang H; Fan Y; Gong S; Wei F; Diao Y; Tang Y
Bioconjug Chem; 2022 Jun; 33(6):1232-1240. PubMed ID: 35586918
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas13a induced exponential amplification for highly sensitive and specific detection of circular RNA.
Song P; Zhang P; Qin K; Su F; Gao K; Liu X; Li Z
Talanta; 2022 Aug; 246():123521. PubMed ID: 35533568
[TBL] [Abstract][Full Text] [Related]
14. Ultrasensitive electrochemical assay for microRNA-21 based on CRISPR/Cas13a-assisted catalytic hairpin assembly.
Cui Y; Fan S; Yuan Z; Song M; Hu J; Qian D; Zhen D; Li J; Zhu B
Talanta; 2021 Mar; 224():121878. PubMed ID: 33379087
[TBL] [Abstract][Full Text] [Related]
15. Plasmonically Enhanced CRISPR/Cas13a-Based Bioassay for Amplification-Free Detection of Cancer-Associated RNA.
Liu L; Wang Z; Wang Y; Luan J; Morrissey JJ; Naik RR; Singamaneni S
Adv Healthc Mater; 2021 Oct; 10(20):e2100956. PubMed ID: 34369102
[TBL] [Abstract][Full Text] [Related]
16. Soluble interleukin-2 receptors in patients with nasopharyngeal carcinoma.
Lai KN; Ho S; Leung JC; Tsao SY
Cancer; 1991 Apr; 67(8):2180-5. PubMed ID: 1848475
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapeutic approaches in nasopharyngeal carcinoma.
Chow JC; Ngan RK; Cheung KM; Cho WC
Expert Opin Biol Ther; 2019 Nov; 19(11):1165-1172. PubMed ID: 31361154
[No Abstract] [Full Text] [Related]
18. Soluble interleukin-2 receptor as a clinical parameter for nasopharyngeal carcinoma.
Hsu MM; Chen YJ; Chang YL; Ko JY; Sheen TS
Asian Pac J Allergy Immunol; 1995 Jun; 13(1):1-4. PubMed ID: 7488337
[TBL] [Abstract][Full Text] [Related]
19. Circulating Epstein-Barr virus microRNAs miR-BART7 and miR-BART13 as biomarkers for nasopharyngeal carcinoma diagnosis and treatment.
Zhang G; Zong J; Lin S; Verhoeven RJ; Tong S; Chen Y; Ji M; Cheng W; Tsao SW; Lung M; Pan J; Chen H
Int J Cancer; 2015 Mar; 136(5):E301-12. PubMed ID: 25213622
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
Qian X; Chen H; Tao Y
Front Immunol; 2023; 14():1146898. PubMed ID: 37063822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
